Black Diamond Therapeutics (BDTX) versus Its Rivals Financial Survey

Black Diamond Therapeutics (NASDAQ:BDTX) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Black Diamond Therapeutics to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, valuation, risk, dividends and earnings.

Risk and Volatility

Black Diamond Therapeutics has a beta of 3.32, indicating that its share price is 232% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics’ rivals have a beta of 1.07, indicating that their average share price is 7% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Black Diamond Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1	2	7	0	2.60
Black Diamond Therapeutics Competitors	9770	15029	45237	1570	2.54

Black Diamond Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 517.98%. As a group, “Biotechnology” companies have a potential upside of 95.42%. Given Black Diamond Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Black Diamond Therapeutics is more favorable than its rivals.

Earnings & Valuation

This table compares Black Diamond Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Diamond Therapeutics	$70.00 million	$22.37 million	-2.37
Black Diamond Therapeutics Competitors	$737.75 million	$13.23 million	-10.05

Black Diamond Therapeutics’ rivals have higher revenue, but lower earnings than Black Diamond Therapeutics. Black Diamond Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Black Diamond Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Black Diamond Therapeutics Competitors	-9,054.31%	-198.21%	-30.53%

Summary

Black Diamond Therapeutics beats its rivals on 10 of the 13 factors compared.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.